Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Videos

Here are the top 5 biosimilar articles for the week of May 29, 2023.

The Top 5 Biosimilar Articles for the Week of May 29

Articles

The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.

Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar

Over the course of May, the immunology biosimilar space bloomed, with a European approval, a delay for ustekinumab biosimilars, more clinical trial updates, and insights into the industry from multiple immunology experts.

Biosimilars Immunology Roundup: May 2023

The European Commission has granted marketing authorization to the first biosimilar referencing Soliris (eculizumab). The product, dubbed Epysqli, was developed by Samsung Bioepis and is the first hematology biosimilar from the company to be approved in the European Union.

First Eculizumab Biosimilar Approved in Europe

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Regulation, Policy, and Litigation in Biosimilars

Biosimilar Interchangeability and Market Share

Interchangeability and Rheumatology Prescribing Practices

Biosimilars, Interchangeability, and Perceptions of Safety

Global Reference Products in Biosimilar Development

Inspection Reports and Proprietary Information

Reforms at the FDA Level

Biosimilars, Formularies, Contracting, and PBMs

Biosimilar Uptake and Health Plans

CMS and Blended Reimbursement Codes

Healthcare Reform Efforts and the BPCIA

State Laws and Biosimilar Substitution

The PTAB's Role in Biosimilar Patent Disputes

The Need for Clarity After <i>Sandoz v Amgen</i>

Upcoming Patent Litigation in Biosimilars

Challenges Ahead for Biosimilars